ADVISORY, July 29, 2013 (GLOBE NEWSWIRE) -- What: Sunshine Heart, Inc. [SSH], an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse® System for treatment of Class III and ambulatory Class IV heart failure, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, David Rosa, CEO will ring the Opening Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Tuesday, July 30, 2013 – 9:15 a.m. to 9:30 a.m. ET Contact: Jeff Mathiesen (952) 345-4200 firstname.lastname@example.org NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com Feed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Facebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ . For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx . Webcast: A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx . Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice. About Sunshine Heart, Inc. [SSH]: Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical trial of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal trial. In July 2012 Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. The Company has initiated its pivotal trial in the U.S. as well as a post market trial in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Australia. The Company has been listed on the NASDAQ Capital Market since February 2012.